Funding sources Funding for the trial was provided by the U.K. Technology Strategy Board, Dystrophic Epidermolysis Bullosa Research Association (UK) and Intercytex Ltd. The cells and vehicle for this trial were manufactured by Intercytex Ltd and supplied without cost for the trial. G.P., M.M.-Q., J.E.M. and J.A.M. are supported by the U.K. National Institute for Health Research (NIHR) Biomedical Research Centre and the Clinical Research Facilities based at Guy's and St Thomas' NHS Foundation Trust and King's College, London.
Clinical and Laboratory Investigations
Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial
Version of Record online: 31 OCT 2013
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 5, pages 1025–1033, November 2013
How to Cite
Petrof, G., Martinez-Queipo, M., Mellerio, J.E., Kemp, P. and McGrath, J.A. (2013), Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. British Journal of Dermatology, 169: 1025–1033. doi: 10.1111/bjd.12599
Conflicts of interest P.K. is CEO and Chief Scientific Officer of Intercytex Ltd. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
This trial is registered with www.controlled-trials.com ISRCTN67757229.
- Issue online: 31 OCT 2013
- Version of Record online: 31 OCT 2013
- Accepted manuscript online: 21 AUG 2013 02:40AM EST
- Manuscript Accepted: 17 AUG 2013
- U.K. National Institute for Health Research
- Biomedical Research Centre and the Clinical Research Facilities
- Guy's and St Thomas' NHS Foundation Trust
- King's College
Fig S1. Measurement of erosion size before and after fibroblast/vehicle.
Fig S2. Quality-of-life measurement (trial data collection form).
Table S1. Vehicle – HypoThermosol®-FRS constituents.
Table S2. Independent, blinded to study treatment assessment of clinical digital photographs of study erosions.
Table S3. Pain scores.
Table S4. Quality-of-life measurements.
Appendix S1. Synopsis of recessive dystrophic epidermolysis bullosa therapies, past and present.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.